权益分类	功能权益	普通用户	{{item.name}}会员
{{category.name}}	{{benefitItem.name}}

Rescuing the anti-HIV activity of APOBEC3G with small-molecule chaperons

用小分子伴侣挽救 APOBEC3G 的抗 HIV 活性

基本信息

批准号：
7858536
负责人：
Sergey N. Savinov
金额：
$ 18.27万
依托单位：
PURDUE UNIVERSITY
依托单位国家：
美国
项目类别：
财政年份：
2009
资助国家：
美国
起止时间：
2009-06-05 至 2011-05-31
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/7858536
关键词：
Acquired Immunodeficiency Syndrome Address Affect Antiviral Agents Binding Biochemical Biological Assay Cells Cellular Assay Complex Cyclic Peptides Cytidine Deaminase Defense Mechanisms Development Disease Dominant-Negative Mutation Down-Regulation Drug Delivery Systems Evaluation Genetic Genetic Transcription Genome Goals HIV HIV-1 Human In Situ Infection Intervention Lead Libraries Ligands Membrane Modification Molecular Molecular Chaperones Molecular Weight Mutagenesis Mutation Organism Outcome Outcomes Research Pathogenicity Peptides Pharmaceutical Preparations Phenotype Prevention Property Proteins Recruitment Activity Reporter Reporting Research Resistance Reverse Transcription Role S Phase Scheme Series Single-Stranded DNA Solid Solutions Structure Structure-Activity Relationship System Therapeutic Toxic effect Ubiquitination Validation Vertebral column Viral Viral Genes Viral Genome Viral Proteins Virion Virus Diseases Virus Replication Vision base design drug resistant virus functional group genetic selection global health inhibitor/antagonist mutant novel protein aminoacid sequence protein protein interaction prototype small molecule tool ubiquitin-protein ligase

项目摘要

DESCRIPTION (provided by applicant): In this proposal, we plan to evaluate the potential for developing an antiviral chemotherapeutic strategy based on the intrinsic defense mechanism of human cells: mutagenesis of single-stranded DNA by cytidine deaminase APOBEC3G (A3G). Human immunodeficiency virus 1 (HIV-1) counters this activity by expressing virion infectivity factor (Vif) that downregulates both the activity and stability of A3G. The essential role of Vif in viral proliferation and highly regulated function of A3G make their interaction an attractive target for the resistance-free intervention. Furthermore, a possibility of generating dominant negative HIV-1 mutants in situ through A3G-induced mutagenesis presents a unique opportunity to inactivate HIV in latently infected cells, normally inaccessible to chemotherapeutics. The proposed research is based on the hypothesis that small molecules capable of competing with the Vif for A3G will simultaneously protect the cellular factor from the antagonism displayed by Vif and reduce stability of the viral factor. The challenge of identifying de novo inhibitors of protein-protein interaction will be addressed in this proposal by exploiting the unique power of genetic selection to yield rare solutions. We believe, therefore, that experimental validation of this hypothesis presents a unique opportunity for curbing the progression of HIV infections through a natural defense mechanism in latently infected cells without the danger of evolving resistant phenotypes. We plan to accomplish the following Specific Aims in developing this approach: Specific Aim 1: We will develop and implement a genetic selection scheme for the discovery of potent and selective antagonists of Vif-A3G interaction. Specific Aim 2: We will confirm and characterize Vif-degrading and/or A3G-protecting activities of the selected backbone cyclic peptides using a series of biochemical and cellular assays. Specific Aim 3: We will identify functional motifs important for the activity of the selected sequences and develop their cell-permeable derivatives. The expected outcome of this research will be a series of specific and potent cell-permeable agents capable of protecting A3G from the downregulation by Vif. Our long-term objective is to advance a prototype of a new class of anti-HIV drugs that can address the three existing problems associated with the current strategies: toxicity, resistance and latency. To protect organism against viral infections, human cells have developed a sophisticated defense mechanism involving modifications of viral genes, lethal to virus replication. Unfortunately, human immunodeficiency virus (HIV) is able to counteract this intrinsic protective system making the disease that it causes, Acquired Immunodeficiency Syndrome (AIDS), a global health problem, with no cure or prevention in sight. We propose to develop a novel anti-HIV therapeutic strategy that will rescue the natural antiviral mechanism without the danger of producing drug-resistant viruses.

描述（由申请人提供）：在本提案中，我们计划评估基于人细胞内在防御机制开发抗病毒化疗策略的潜力：通过胞苷脱氨酶APOBEC 3G（A3 G）诱变单链DNA。人类免疫缺陷病毒1型（HIV-1）通过表达病毒粒子感染因子（Vif）来对抗这种活性，该因子可下调A3 G的活性和稳定性。Vif在病毒增殖中的重要作用和A3 G的高度调节功能使得它们的相互作用成为无耐药性干预的有吸引力的靶标。此外，通过A3 G诱导的诱变原位产生显性阴性HIV-1突变体的可能性提供了在潜伏感染的细胞中抑制HIV的独特机会，通常化疗药物无法获得。该研究基于这样的假设，即能够与Vif竞争A3 G的小分子将同时保护细胞因子免受Vif显示的拮抗作用，并降低病毒因子的稳定性。本提案将通过利用遗传选择的独特力量产生罕见的解决方案来解决识别蛋白质-蛋白质相互作用的从头抑制剂的挑战。因此，我们相信，这一假设的实验验证提供了一个独特的机会，通过潜伏感染细胞中的自然防御机制来抑制HIV感染的进展，而不会出现进化耐药表型的危险。我们计划在制定这一方法时实现以下具体目标：具体目标1：我们将开发和实施一种遗传选择方案，用于发现Vif-A3 G相互作用的有效和选择性拮抗剂。具体目标二：我们将使用一系列生物化学和细胞测定来确认和表征所选骨架环肽的VIF降解和/或A3 G保护活性。具体目标3：我们将确定对所选序列的活性重要的功能基序，并开发其细胞渗透衍生物。本研究的预期结果将是一系列特异性和有效的细胞渗透剂，能够保护A3 G免受Vif的下调。我们的长期目标是推进一类新的抗艾滋病毒药物的原型，可以解决与当前策略相关的三个现有问题：毒性，耐药性和潜伏期。为了保护生物体免受病毒感染，人类细胞已经发展了一种复杂的防御机制，涉及病毒基因的修饰，对病毒复制是致命的。不幸的是，人类免疫缺陷病毒（HIV）能够抵消这种内在的保护系统，使它引起的疾病，获得性免疫缺陷综合症（AIDS），成为一个全球性的健康问题，没有治愈或预防的希望。我们建议开发一种新的抗HIV治疗策略，该策略将拯救天然的抗病毒机制，而不会产生耐药病毒的危险。